Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
